Corporate Compliance Programs Are Often Inadequate To Avoid Foreign Corruption Investigations, DoJ Official Says
Pharmaceutical companies have spent a vast amount of resources bolstering their compliance programs in the wake of government investigations of their domestic marketing practices. But their procedures may be insufficient to detect corruption and bribery abroad
You may also be interested in...
Johnson & Johnson agreed to pay $70 million to resolve charges by the Securities and Exchange Commission and the Department of Justice that the company bribed doctors in several European countries to order or prescribe its products in violation of the Foreign Corrupt Practices Act
Pharma companies have been battered by government and congressional investigations of their domestic marketing practices. They now face increased scrutiny on another front as the Department of Justice and the Securities and Exchange Commission are stepping up their investigation of corporate corruption and bribery abroad
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011